Tailor an Options Trading Strategy to Fit Your Needs

From RJO Futures | Ad

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Download your FREE Options Strategy Guide Today.

NBIX Insider Trading (Neurocrine Biosciences)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $12,853,681.31

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$98.40

▼ -0.06 (-0.06%)

As of 06/30/2022 01:18 PM ET

Days: 30 | 90 | 365

Tailor an Options Trading Strategy to Fit Your Needs

From RJO Futures | Ad

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Download your FREE Options Strategy Guide Today.

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/27/2022	Julie Cooke	Insider	Sell	754	$100.00	$75,400.00	16,918
5/9/2022	Richard F. Pops	Director	Sell	15,000	$76.30	$1,144,500.00	29,512
4/25/2022	Gary A. Lyons	Director	Sell	15,000	$92.76	$1,391,400.00	208,697
4/1/2022	William H. Rastetter	Director	Sell	10,728	$94.93	$1,018,409.04	34,022
3/22/2022	Darin Lippoldt	Insider	Sell	8,455	$95.05	$803,647.75
3/18/2022	Darin Lippoldt	Insider	Sell	300	$95.00	$28,500.00
2/7/2022	David W. Boyer	Insider	Sell	240	$81.07	$19,456.80
2/7/2022	Kevin Charles Gorman	CEO	Sell	8,710	$80.82	$703,942.20
2/7/2022	Matt Abernethy	CFO	Sell	3,310	$80.79	$267,414.90
1/24/2022	Stephen A. Sherwin	Director	Sell	15,000	$74.43	$1,116,450.00
1/10/2022	Eiry Roberts	Insider	Sell	2,632	$74.50	$196,084.00
1/5/2022	Kyle Gano	Insider	Sell	28,266	$85.50	$2,416,743.00
12/1/2021	Matt Abernethy	CFO	Sell	1,645	$82.59	$135,860.55
10/7/2021	Dimitri E. Grigoriadis	Insider	Sell	8,000	$104.81	$838,480.00
10/7/2021	Gary A. Lyons	Director	Sell	5,000	$105.06	$525,300.00
10/4/2021	Julie Cooke	Insider	Sell	987	$101.73	$100,407.51
8/16/2021	Eric Benevich	Insider	Sell	5,628	$89.62	$504,381.36
7/27/2021	Malcolm Lloyd-Smith	Insider	Sell	16,709	$93.80	$1,567,304.20	15,801
6/10/2021	Gary A. Lyons	Director	Sell	10,000	$100.27	$1,002,700.00
2/10/2021	Malcolm Lloyd-Smith	Insider	Sell	1,700	$119.96	$203,932.00	33,610
2/8/2021	Eiry Roberts	Insider	Sell	2,363	$116.78	$275,951.14	17,231
2/8/2021	Kevin Charles Gorman	CEO	Sell	10,466	$116.75	$1,221,905.50	443,249
2/8/2021	Matt Abernethy	CFO	Sell	2,910	$116.82	$339,946.20	13,043
2/5/2021	Kevin Charles Gorman	CEO	Sell	2,422	$114.16	$276,495.52	443,249
2/5/2021	Malcolm Lloyd-Smith	Insider	Sell	865	$114.15	$98,739.75	29,675
1/26/2021	Malcolm Lloyd-Smith	Insider	Sell	1,100	$119.97	$131,967.00	33,013
1/25/2021	Gary A. Lyons	Director	Sell	1,600	$120.03	$192,048.00
1/8/2021	Eiry Roberts	Insider	Sell	2,632	$111.06	$292,309.92	15,845
1/8/2021	Kevin Charles Gorman	CEO	Sell	308,250	$110.22	$33,975,315.00	584,520
12/1/2020	Matt Abernethy	CFO	Sell	1,645	$94.66	$155,715.70	11,494
11/12/2020	Eric Benevich	Insider	Sell	2,257	$90.71	$204,732.47	17,405
11/12/2020	Kevin Charles Gorman	CEO	Sell	3,390	$90.78	$307,744.20	441,071
11/2/2020	Eric Benevich	Insider	Sell	20,595	$96.53	$1,988,035.35	35,969
10/2/2020	Julie Cooke	Insider	Sell	987	$95.26	$94,021.62	9,549
8/5/2020	Eiry Roberts	Insider	Sell	2,257	$118.84	$268,221.88	11,446
8/5/2020	Kevin Charles Gorman	CEO	Sell	3,390	$118.91	$403,104.90	438,021
7/9/2020	Darin Lippoldt	Insider	Sell	1,657	$136.02	$225,385.14	27,678
6/23/2020	Eiry Roberts	Insider	Sell	5,000	$130.00	$650,000.00	14,416
5/18/2020	Darin Lippoldt	Insider	Sell	5,000	$120.00	$600,000.00	31,021
5/12/2020	Haig P Bozigian	Insider	Sell	61,555	$114.94	$7,075,131.70	157,727
5/7/2020	Dimitri E. Grigoriadis	Insider	Sell	8,682	$105.44	$915,430.08	104,741
5/7/2020	Matt Abernethy	CFO	Sell	15,000	$110.21	$1,653,150.00	20,953
4/28/2020	Matt Abernethy	CFO	Sell	1,741	$102.49	$178,435.09	5,953
4/28/2020	Stephen A. Sherwin	Director	Sell	17,687	$99.39	$1,757,910.93	29,861
4/24/2020	Eiry Roberts	Insider	Sell	1,934	$99.47	$192,374.98
4/24/2020	Kevin Charles Gorman	CEO	Sell	2,906	$99.45	$289,001.70	434,971
4/15/2020	Eric Benevich	Insider	Sell	8,632	$94.65	$817,018.80
2/10/2020	Malcolm Lloyd-Smith	Insider	Sell	28,969	$104.56	$3,028,998.64	23,200
2/7/2020	Eiry Roberts	Insider	Sell	1,623	$103.31	$167,672.13	7,452
2/7/2020	Kevin Charles Gorman	CEO	Sell	3,248	$103.35	$335,680.80	432,357
2/7/2020	Matt Abernethy	CFO	Sell	2,030	$103.35	$209,800.50	5,701
2/5/2020	Kevin Charles Gorman	CEO	Sell	5,449	$103.09	$561,737.41	423,351
2/5/2020	Kyle Gano	Insider	Sell	3,690	$103.05	$380,254.50
1/8/2020	Eiry Roberts	Insider	Sell	2,632	$111.11	$292,441.52
12/2/2019	Matt Abernethy	CFO	Sell	1,645	$116.33	$191,362.85
11/18/2019	Dimitri E. Grigoriadis	Insider	Sell	5,000	$115.98	$579,900.00	113,408
11/8/2019	Darin Lippoldt	Insider	Sell	10,000	$110.01	$1,100,100.00	26,728
11/8/2019	Gary A. Lyons	Director	Sell	5,000	$110.00	$550,000.00	225,697
11/1/2019	Dimitri E. Grigoriadis	Insider	Sell	10,188	$100.34	$1,022,263.92	118,596
11/1/2019	Gary A. Lyons	Director	Sell	5,000	$100.22	$501,100.00	230,697
10/14/2019	Malcolm Lloyd-Smith	Insider	Sell	9,956	$90.85	$904,502.60
10/2/2019	Julie Cooke	Insider	Sell	987	$88.56	$87,408.72
9/3/2019	Darin Lippoldt	Insider	Sell	6,736	$100.00	$673,600.00
8/27/2019	Darin Lippoldt	Insider	Sell	3,264	$100.05	$326,563.20	21,625
8/23/2019	Darin Lippoldt	Insider	Sell	1,664	$100.09	$166,549.76	21,625
8/8/2019	Kevin Charles Gorman	CEO	Sell	80,000	$95.31	$7,624,800.00	468,508
8/6/2019	Kevin Charles Gorman	CEO	Sell	50,911	$95.15	$4,844,181.65	468,508
7/30/2019	Darin Lippoldt	Insider	Sell	15,831	$92.13	$1,458,510.03	160,732
7/30/2019	Gary A. Lyons	Director	Sell	10,000	$92.07	$920,700.00	235,697
7/15/2019	Eric Benevich	Insider	Sell	5,835	$87.44	$510,212.40	14,910
7/11/2019	Haig P Bozigian	Insider	Sell	7,220	$87.63	$632,688.60	149,096

1 Stock With Growth Potential

From Wealthy Millionaire | Ad

This could be one of the best stocks to consider during this bear market run.

Click for ticker & full details

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

93.21% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
6/7/2022	Teachers Retirement System of The State of Kentucky	21,145	$1.98M	0.0%	+47.9%	0.022%
6/2/2022	Verition Fund Management LLC	103,534	$9.71M	0.1%	-55.9%	0.108%
6/2/2022	Mirae Asset Global Investments Co. Ltd.	38,442	$3.61M	0.0%	-11.6%	0.040%
5/27/2022	Walleye Capital LLC	25,533	$2.39M	0.0%	-10.0%	0.027%
5/23/2022	Neuberger Berman Group LLC	7,482	$0.70M	0.0%	+65.0%	0.008%
5/20/2022	International Biotechnology Trust PLC	203,000	$3.15M	0.7%	-27.5%	0.212%
5/20/2022	The Manufacturers Life Insurance Company	99,911	$9.34M	0.0%	-6.8%	0.105%
5/20/2022	Toroso Investments LLC	3,144	$0.30M	0.0%	+14.7%	0.003%
5/19/2022	Capital International Investors	47,027	$4.41M	0.0%	-18.3%	0.049%
5/18/2022	BNP Paribas Arbitrage SA	50,626	$4.75M	0.0%	-83.7%	0.053%
5/17/2022	Walleye Capital LLC	25,533	$2.39M	0.0%	-10.0%	0.027%
5/17/2022	Walleye Trading LLC	6,519	$0.61M	0.0%	+24.3%	0.007%
5/17/2022	Weiss Multi Strategy Advisers LLC	20,000	$1.88M	0.0%	-41.4%	0.021%
5/17/2022	Advisors Asset Management Inc.	15,435	$1.45M	0.0%	-18.1%	0.016%
5/17/2022	Penn Capital Management Company LLC	3,567	$0.33M	0.0%	+24.0%	0.004%
5/17/2022	Meiji Yasuda Asset Management Co Ltd.	6,310	$0.59M	0.0%	-1.9%	0.007%
5/17/2022	Point72 Hong Kong Ltd	6,951	$0.65M	0.0%	+165.3%	0.007%
5/17/2022	Polar Capital Holdings Plc	759,287	$71.18M	0.3%	+2,114.5%	0.794%
5/17/2022	Eaton Vance Management	1,456,048	$136.50M	0.2%	-21.2%	1.523%
5/17/2022	Ensign Peak Advisors Inc	65,990	$6.19M	0.0%	-8.2%	0.069%
5/17/2022	First Republic Investment Management Inc.	10,852	$1.02M	0.0%	+62.9%	0.011%
5/17/2022	Guggenheim Capital LLC	57,282	$5.37M	0.0%	-7.9%	0.060%
5/16/2022	California State Teachers Retirement System	156,173	$14.64M	0.0%	-5.7%	0.163%
5/16/2022	Deerfield Management Company L.P. Series C	1,657,800	$155.42M	3.5%	+20.3%	1.735%
5/16/2022	Brinker Capital Investments LLC	33,474	$3.14M	0.0%	+23.8%	0.035%
5/16/2022	Woodline Partners LP	259,635	$24.34M	0.4%	+103.4%	0.272%
5/16/2022	Wellington Management Group LLP	389,408	$36.51M	0.0%	N/A	0.407%
5/16/2022	Echo Street Capital Management LLC	5,536	$0.52M	0.0%	-33.3%	0.006%
5/16/2022	Engineers Gate Manager LP	3,723	$0.35M	0.0%	+35.5%	0.004%
5/16/2022	Atria Wealth Solutions Inc.	4,596	$0.43M	0.0%	N/A	0.005%
5/16/2022	Hood River Capital Management LLC	180,557	$16.93M	0.6%	+2.1%	0.189%
5/16/2022	Hsbc Holdings PLC	58,156	$5.45M	0.0%	+9.0%	0.061%
5/13/2022	Silverarc Capital Management LLC	20,482	$1.92M	0.8%	N/A	0.021%
5/13/2022	Rhenman & Partners Asset Management AB	105,000	$9.84M	1.0%	-30.5%	0.110%
5/13/2022	Renaissance Technologies LLC	1,280,123	$120.01M	0.1%	-10.1%	1.339%
5/13/2022	Bellevue Group AG	3,023,451	$283.45M	3.3%	-4.9%	3.163%
5/13/2022	Ontario Teachers Pension Plan Board	4,786	$0.45M	0.0%	N/A	0.005%
5/13/2022	Northern Trust Corp	883,091	$82.79M	0.0%	+1.0%	0.924%
5/13/2022	Verition Fund Management LLC	103,534	$9.71M	0.1%	-55.9%	0.108%
5/13/2022	Charles Schwab Investment Management Inc.	520,849	$48.83M	0.0%	+2.2%	0.545%
5/13/2022	Edgestream Partners L.P.	26,123	$2.45M	0.2%	-43.3%	0.027%
5/13/2022	Lazard Asset Management LLC	791	$74K	0.0%	-98.4%	0.001%
5/13/2022	Utah Retirement Systems	16,683	$1.56M	0.0%	-1.8%	0.017%
5/13/2022	Mariner LLC	10,796	$1.01M	0.0%	N/A	0.011%
5/13/2022	Nelson Van Denburg & Campbell Wealth Management Group LLC	5,832	$0.55M	0.0%	-35.0%	0.006%
5/13/2022	Caisse DE Depot ET Placement DU Quebec	24,769	$2.32M	0.0%	+37.8%	0.026%
5/13/2022	Arrowstreet Capital Limited Partnership	96,283	$9.03M	0.0%	-14.3%	0.101%
5/13/2022	First Trust Advisors LP	640,459	$60.04M	0.1%	+7.3%	0.670%
5/13/2022	Prudential Financial Inc.	60,851	$5.71M	0.0%	+178.0%	0.064%
5/13/2022	Federated Hermes Inc.	33,110	$3.10M	0.0%	-12.1%	0.035%
5/13/2022	USS Investment Management Ltd	8,386	$0.79M	0.0%	-59.6%	0.009%
5/13/2022	American International Group Inc.	161,492	$15.14M	0.1%	+0.2%	0.169%
5/13/2022	Bridgewater Associates LP	5,020	$0.47M	0.0%	+98.7%	0.005%
5/13/2022	Parkman Healthcare Partners LLC	63,234	$5.93M	1.7%	N/A	0.066%
5/13/2022	Mackenzie Financial Corp	29,896	$2.80M	0.0%	+193.3%	0.031%
5/13/2022	Covestor Ltd	377	$35K	0.0%	+431.0%	0.000%
5/13/2022	Loomis Sayles & Co. L P	2,033	$0.19M	0.0%	N/A	0.002%
5/13/2022	Candriam Luxembourg S.C.A.	300,207	$28.14M	0.2%	-3.1%	0.314%
5/13/2022	Vanguard Group Inc.	8,777,458	$822.89M	0.0%	-0.1%	9.183%
5/13/2022	Rothschild & Co. Asset Management US Inc.	78,514	$7.36M	0.1%	-22.5%	0.082%
5/13/2022	Allianz Asset Management GmbH	266,022	$24.94M	0.0%	+33.8%	0.278%
5/13/2022	Canada Pension Plan Investment Board	3,900	$0.37M	0.0%	-84.4%	0.004%
5/13/2022	DSM Capital Partners LLC	1,351,331	$126.69M	1.7%	-4.0%	1.414%
5/13/2022	Blair William & Co. IL	10,530	$0.99M	0.0%	-31.3%	0.011%
5/13/2022	Vontobel Holding Ltd.	40,095	$3.71M	0.0%	+83.3%	0.042%
5/13/2022	Dimensional Fund Advisors LP	417,604	$39.15M	0.0%	+39.1%	0.437%
5/12/2022	Integral Health Asset Management LLC	35,000	$3.28M	0.9%	N/A	0.037%
5/12/2022	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	14,645	$1.37M	0.0%	-11.8%	0.015%
5/12/2022	Yousif Capital Management LLC	52,027	$4.88M	0.1%	+3.3%	0.054%
5/12/2022	Great West Life Assurance Co. Can	98,938	$9.67M	0.0%	-5.9%	0.104%
5/12/2022	APG Asset Management N.V.	321,910	$27.12M	0.1%	-0.2%	0.337%
5/12/2022	Commonwealth of Pennsylvania Public School Empls Retrmt SYS	34,768	$3.26M	0.0%	+10.5%	0.036%
5/12/2022	Rhumbline Advisers	255,264	$23.93M	0.0%	+0.1%	0.267%
5/12/2022	MetLife Investment Management LLC	65,509	$6.14M	0.0%	+42.5%	0.069%
5/12/2022	Acadian Asset Management LLC	293	$27K	0.0%	N/A	0.000%
5/12/2022	Bank of Montreal Can	82,743	$7.67M	0.0%	-25.3%	0.087%
5/12/2022	Natixis Advisors L.P.	60,349	$5.66M	0.0%	+118.6%	0.063%
5/12/2022	E Fund Management Co. Ltd.	3,005	$0.28M	0.0%	N/A	0.003%
5/12/2022	AlphaCrest Capital Management LLC	17,400	$1.63M	0.1%	-45.4%	0.018%
5/12/2022	PNC Financial Services Group Inc.	3,150	$0.30M	0.0%	+27.7%	0.003%
5/12/2022	Citigroup Inc.	61,805	$5.79M	0.0%	-78.2%	0.065%
5/12/2022	Mitsubishi UFJ Trust & Banking Corp	84,038	$7.88M	0.0%	-12.8%	0.088%
5/12/2022	Connor Clark & Lunn Investment Management Ltd.	209,599	$19.65M	0.1%	+302.4%	0.219%
5/12/2022	Lisanti Capital Growth LLC	42,210	$3.96M	0.4%	N/A	0.044%
5/12/2022	Oppenheimer & Co. Inc.	12,122	$1.14M	0.0%	-1.3%	0.013%
5/12/2022	HighTower Advisors LLC	5,745	$0.54M	0.0%	+48.8%	0.006%
5/12/2022	Blueshift Asset Management LLC	2,654	$0.25M	0.0%	-39.1%	0.003%
5/11/2022	US Bancorp DE	31,115	$2.92M	0.0%	+44.1%	0.033%
5/11/2022	American Century Companies Inc.	795,848	$74.61M	0.1%	+534.5%	0.833%
5/11/2022	Bank of New York Mellon Corp	1,703,093	$159.67M	0.0%	-8.5%	1.782%
5/11/2022	Coldstream Capital Management Inc.	2,232	$0.21M	0.0%	N/A	0.002%
5/11/2022	Handelsbanken Fonder AB	15,267	$1.43M	0.0%	+50.2%	0.016%
5/11/2022	Massachusetts Financial Services Co. MA	217,099	$20.35M	0.0%	+2.8%	0.227%
5/11/2022	Raymond James & Associates	79,746	$7.48M	0.0%	+21.5%	0.083%
5/11/2022	Twin Tree Management LP	11,847	$1.11M	0.0%	+324.0%	0.012%
5/11/2022	NN Investment Partners Holdings N.V.	14,377	$1.35M	0.0%	-31.0%	0.015%
5/11/2022	Skandinaviska Enskilda Banken AB publ	155,253	$14.56M	0.1%	+1.1%	0.162%
5/11/2022	WINTON GROUP Ltd	36,507	$3.42M	0.2%	-9.8%	0.038%
5/10/2022	South Dakota Investment Council	3,247	$0.30M	0.0%	-83.8%	0.003%
5/10/2022	Profund Advisors LLC	15,578	$1.46M	0.1%	-9.8%	0.016%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $98.40

$96.39

$98.42

50 Day Range

MA: $90.72

$75.79

$99.93

52 Week Range

Now: $98.40

$71.88

$108.01

Volume

4,660 shs

Average Volume

807,060 shs

Market Capitalization

$9.40 billion

P/E Ratio

136.75

Dividend Yield

N/A

Beta

0.7

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Eric Benevich (Insider)
William H Rastetter (Director)
Malcolm Lloyd-Smith (Insider)
Richard F Pops (Director)
Darin Lippoldt (Insider)
Eiry Roberts (Insider)
Julie Cooke (Insider)
Matt Abernethy (CFO)
David W Boyer (Insider)
Dimitri E Grigoriadis (Insider)
Kyle Gano (Insider)
Stephen A Sherwin (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
Vanguard Group Inc. — 9.18%
Bellevue Group AG — 3.16%
Bank of New York Mellon Corp — 1.78%
Deerfield Management Company L.P. Series C — 1.73%
Eaton Vance Management — 1.52%
DSM Capital Partners LLC — 1.41%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
Eaton Vance Management
Zurcher Kantonalbank Zurich Cantonalbank
BNP Paribas Arbitrage SA
Citigroup Inc.
Bank of New York Mellon Corp
Bellevue Group AG
Renaissance Technologies LLC
Verition Fund Management LLC
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Eric Benevich (Insider)
William H Rastetter (Director)
Malcolm Lloyd-Smith (Insider)
Richard F Pops (Director)
Darin Lippoldt (Insider)
Eiry Roberts (Insider)
Julie Cooke (Insider)
Matt Abernethy (CFO)
David W Boyer (Insider)
Dimitri E Grigoriadis (Insider)
Kyle Gano (Insider)
Stephen A Sherwin (Director)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
Polar Capital Holdings Plc
American Century Companies Inc.
Wellington Management Group LLP
Deerfield Management Company L.P. Series C
GW&K Investment Management LLC
Congress Asset Management Co. MA
Connor Clark & Lunn Investment Management Ltd.
Rice Hall James & Associates LLC

Tailor an Options Trading Strategy to Fit Your Needs

From RJO Futures | Ad

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Download your FREE Options Strategy Guide Today.

NBIX Insider Trading (Neurocrine Biosciences)

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

Neurocrine Biosciences Insider Trading History

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Neurocrine Biosciences?

Who are the major institutional investors of Neurocrine Biosciences?

Which institutional investors are selling Neurocrine Biosciences stock?

Which institutional investors are buying Neurocrine Biosciences stock?